A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions

Atopic Dermatitis

Interventions

DRUG

Dupilumab

Trial Locations (26)

Markham

Peterborough

Waterloo

Windsor

Kutná Hora

Prague

Dresden

Frankfurt

Gera

Hamburg

Kiel

Lübeck

Munich

Münster

Tübingen

Kaposvár

Miskolc

Szeged

Szolnok

Katowice

Krakow

Lodz

Warsaw

Wroclaw

Manchester

Sheffield